Six research-led modules — what the 2023 reanalyses actually changed, how to qualify for the 10-year window, the conversation framework with your doctor, the dosing-and-titration questions to ask, the side-effect navigation, and the long-term follow-up plan. The course women take before their first menopause-trained-clinician visit.
Founder's Price · Limited
Full course access — six modules, lifetime access.
Module previews are below. Full content unlocks instantly after purchase. 60-day money-back guarantee. No subscription, no recurring charges. Lifetime updates included.
The 2024 reframe — what actually changed about HRT.
The 2002 WHI study scared a generation of doctors out of prescribing HRT. Within 18 months, prescriptions dropped 80%. An estimated 18,601 women died of hip fractures between 2002 and 2011 who would not have died if HRT prescribing had continued at pre-2002 rates.
What almost nobody mentions: the average woman in the 2002 WHI study was 63 years old. The average woman starting HRT in real practice was — and is — 52 years old. Eleven years matters. A lot.
The 2023 reanalysis
Hodis & Mack, Climacteric 2023, ran the WHI data sliced by age at initiation. Women who started HRT within 10 years of their final period showed:
31% lower all-cause mortality
52% lower coronary heart disease
50% lower Alzheimer's risk
A breast cancer signal that was barely statistically significant — and went away when adjusted for the synthetic progestin (medroxyprogesterone) almost never prescribed anymore
The "HRT causes cancer" story was based on the wrong drug, given to the wrong age group, then generalized to everyone. That's the conversation update most doctors haven't received.
Module 1 is freely available because the reframe is the part that needs to spread. Modules 2-6 are member-only.
Module 2 of 6
The 10-year window — where do you fall, exactly?
The single most important variable in the HRT decision is timing relative to your final period. Inside the 10-year window, the cardiovascular and bone benefits dominate. Outside it, the risk-benefit shifts.
How to determine your window position
If you still have periods — even irregular ones — you are in perimenopause. The window has not yet started counting. Any HRT decision at this stage is about symptom management, not the 10-year window calculation.
If you have not had a period in 12 consecutive months — that 12-month mark is your "final menstrual period" (FMP) by definition. The 10-year window started the month after.
If you don't know your exact FMP date — this is common because women often don't realize the last period was the last one. Use the calendar of your last 3-5 periods to triangulate. An estimate within 6 months is fine for clinical purposes.
The decision matrix
Years since FMP
Risk-benefit shape
Typical recommendation
Perimenopause (still cycling)
Mostly symptom-driven
Discuss; usually combined estrogen + progesterone
0-5 years post-FMP
Maximum benefit, lowest risk
Strongly favorable for most candidates
5-10 years post-FMP
Still net benefit
Favorable for most candidates
10-15 years post-FMP
Mixed; depends on baseline cardiovascular risk
Requires specialist consultation
15+ years post-FMP
Risk-benefit shifts unfavorable
Generally not initiated; topical-only exceptions
The contraindications that actually matter
The list of "things that disqualify you from HRT" is shorter than most women have been told. The real contraindications:
Active breast cancer (current diagnosis or active treatment)
History of estrogen-receptor-positive breast cancer (relative — case-by-case with oncology)
Active blood clot or stroke history (oral estrogen contraindicated; transdermal often still possible)
Untreated severe liver disease
Unexplained vaginal bleeding (workup first, then decide)
Things that are not contraindications despite being often cited as such: family history of breast cancer (modest risk modifier, not contraindication), fibroids (manageable), endometriosis history (manageable), migraines without aura, well-controlled hypertension, type 2 diabetes, obesity.
Module 3 of 6
The clinician conversation — exact questions to bring.
Most primary care physicians and many OB/GYNs have not updated their HRT framework since 2008. The conversation goes better when you bring specific, current questions.
The opening line that signals you've done the reading
What to say
"I'd like to have a structured conversation about HRT initiation. Based on my age and time since final period, I'm in the [number]-year window. I've read the Hodis-Mack 2023 reanalysis and I'd like to understand my risk-benefit profile."
This opening accomplishes three things: signals you're informed, anchors the conversation on the modern evidence (not 2002 panic), and gives the doctor a structured way to respond.
The 12 questions that move the conversation forward
"Have you read the Hodis-Mack 2023 reanalysis? Where do I fall in the 10-year window?"
"Given my baseline cardiovascular risk, what's the projected benefit on coronary heart disease for me specifically?"
"What's the most current bone density recommendation for me? Should we get a DEXA before or after the HRT decision?"
"Which formulation do you typically start with — oral estradiol, transdermal patch, or vaginal-only?"
"For progesterone, do you prescribe oral micronized (Prometrium) or synthetic (medroxyprogesterone)? What's your reasoning?"
"What's your typical starting dose? How quickly do you titrate?"
"What symptoms or signs would tell us the dose is right? Too low? Too high?"
"What's the follow-up cadence — bloodwork, imaging, symptom check?"
"At what point would we adjust or discontinue?"
"What contraindications am I missing or under-weighting in my own case?"
"What's the long-term plan? Most modern guidance is that there's no fixed end date — at what point does that change for me?"
"If we proceed, what should I be tracking at home? Temperature, sleep, mood, libido, weight?"
How to handle pushback
If the doctor reflexively cites the 2002 WHI panic, this is the moment to ask: "Have you read the 2023 update? My understanding is that the modern evidence has shifted substantially. Would you be open to looking at the Hodis-Mack paper, or would you prefer to refer me to a NAMS-certified menopause practitioner for this conversation?"
The NAMS (now Menopause Society) certification matters because it's the credential that signals current evidence-base. The directory is at menopause.org.
Module 4 of 6
Formulation, dose, and titration — the practical mechanics.
Once the decision to initiate is made, the next layer of decisions is about formulation and dose. These decisions are where outcomes diverge significantly.
This is the most under-discussed decision in HRT prescribing. If you have a uterus, you need progesterone with your estrogen to protect the endometrium. Bioidentical micronized progesterone (Prometrium) has a meaningfully different risk profile than the synthetic progestin (medroxyprogesterone acetate) used in the 2002 WHI study.
Most of the cancer signal in WHI came from the synthetic progestin, not from estrogen. Modern prescribing increasingly defaults to bioidentical. If your doctor reaches for medroxyprogesterone reflexively, ask why.
Bioidentical micronized progesterone, taken at bedtime, has the additional benefit of promoting deep sleep — many women report sleep improvement within days of starting.
Titration schedule
Most starting protocols use the low end of the dose range for 4-8 weeks, then assess symptoms and titrate. Symptom resolution within 4 weeks suggests the dose is approximately right. Persistent symptoms or breakthrough bleeding suggest dose adjustment.
The follow-up cadence in modern practice: bloodwork at baseline, 3 months, then annually. Bone density at baseline (DEXA), then every 2-5 years.
Module 5 of 6
Side effects, monitoring, and when to adjust.
Most women on HRT do well. A meaningful minority experience side effects that need management. The first 4-6 weeks is the highest-attention window.
Common side effects in the first month
Breast tenderness — common, usually fades. If persistent at 2 months, consider lower estrogen dose.
Bloating — usually from the progesterone. Switching to bedtime dosing often helps.
Mood changes — can be the progesterone causing low mood or sedation. Try different progesterone schedule or formulation.
Headaches — usually settle. If new migraines start, consult prescriber.
Spotting or breakthrough bleeding — common in first 3 months, especially on continuous regimens. Persistent bleeding past 6 months needs evaluation.
Red flags requiring prompt contact
Calf swelling or pain (clot suspicion)
Sudden severe headache or visual changes
Chest pain or shortness of breath
Heavy or prolonged vaginal bleeding
New lump in breast
Tracking that helps the conversation
The single most useful home tracking for HRT titration: basal body temperature, sleep stages, and a daily 1-10 mood + energy score. An Oura, Apple Watch, or simple journal works. Bring 4 weeks of data to follow-up appointments.
Optional advanced: HRV (heart rate variability) tracking. Trends matter more than absolute numbers.
Module 6 of 6
The long-term plan — annual review, dose adjustment, when (if) to stop.
Modern guidance increasingly does not put a fixed end date on HRT. The decision to continue, adjust, or stop is a yearly review based on ongoing risk-benefit assessment.
Discussion of any new risk factors (cancer in family, cardiovascular events, etc.)
Dose-down considerations
Some women find their needed dose decreases over time as symptoms naturally attenuate. Reasonable to attempt a step-down every 2-3 years, with awareness that some women feel substantially worse on lower doses and benefit from returning to their effective dose.
If you decide to stop
Most modern guidance favors gradual taper over abrupt discontinuation, especially for women on systemic estrogen. Rapid discontinuation can cause a return of vasomotor symptoms within days and is unnecessary in most cases. A 3-6 month gradual taper is usually well tolerated.
Bone density loss resumes when systemic estrogen is discontinued. The bone benefit accrued during HRT is not permanent. This is one reason many women choose to continue indefinitely rather than discontinue at an arbitrary age.
Living document — updates
This course will be updated as the evidence base evolves. Members get automatic access to all future updates. Major update cadence: roughly twice per year as new trial data publishes.
The single most important variable in the HRT decision is timing relative to your final period. Inside the 10-year window, the cardiovascular and bone benefits dominate. Outside it, the risk-benefit shifts.
How to determine your window position
If you still have periods — even irregular ones — you are in perimenopause. The window has not yet started counting. Any HRT decision at this stage is about symptom management, not the 10-year window calculation...
Unlock the full course
Modules 2-6 — instant access on purchase.
The decision matrix, the 12 clinician questions, the formulation comparison, the side-effect navigation, and the long-term plan. Lifetime access. Lifetime updates. 60-day money-back.